Synergistic interaction between docosahexaenoic acid and diclofenac on inflammation, nociception, and gastric security models in rats

被引:9
作者
Allan Miranda-Lara, Christopher [1 ]
Ortiz, Mario I. [2 ]
Rodriguez-Ramos, Fernando [3 ]
Evangelina Chavez-Pina, Aracely [1 ,4 ]
机构
[1] Inst Politecn Nacl, Escuela Nacl Med & Homeopatia, Ciencias Biomed Mol, Guillermo Massieu Helguera 239, Mexico City 07320, DF, Mexico
[2] Univ Autonoma Estado Hidalgo, Inst Ciencias Salud, Area Acad Med, Pachuca, Hidalgo, Mexico
[3] Univ Autonoma Metropolitana Xochimilco, Dept Sistemas Biol, Div Ciencias Biol & Salud, Mexico City, DF, Mexico
[4] Inst Politecn Nacl, Escuela Nacl Med & Homeopatia, Lab Farmacol, Ciencias Biotecnol, Mexico City, DF, Mexico
关键词
diclofenac; docosahexaenoic acid; gastric damage; synergism; inflammation; nociception; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; EICOSAPENTAENOIC ACID; FORMALIN TEST; K+ CHANNELS; INDOMETHACIN; PAIN; SAFETY; DAMAGE; MICE; OMEGA-3-FATTY-ACIDS;
D O I
10.1002/ddr.21438
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The addition of polyunsaturated fatty acids to nonsteroidal anti-inflammatory drugs can increase their antinociceptive activity and produce a gastroprotective effect. The aim of the present study was to examine the effects of the interaction between docosahexaenoic acid (DHA) and diclofenac on inflammation (fixed ratios 1:1, 1:3, and 3:1), nociception (fixed ratio 1:3), and gastric injury in rats. DHA, diclofenac, or combinations of DHA and diclofenac produced anti-inflammatory and antinociceptive effects in rat. The administration of diclofenac produced significant gastric damage, but this effect was not observed with either DHA or the DHA-diclofenac combinations. Effective dose (ED30) values were estimated for each individual drug and analyzed isobolographically. The anti-inflammatory experimental ED30 values were 6.97mg/kg (1:1 fixed ratio), 1.1 mg/kg (1:3 fixed ratio), and 11.34mg/kg (3:1 fixed ratio). These values were significantly lower (p< .05) than the theoretical ED30 values: 67.94mg/kg (1:1), 35.37mg/kg (1:3), and 100.51mg/kg (3:1). The antinociceptive experimental value was 1.25mg/kg (1:3 fixed ratio). This value was lower (p<.05) than the theoretical ED30, which was predicted to be 15.92mg/kg. These data indicate that the DHA-diclofenac combinations interact at the systemic level, produce minor gastric damage, and potentially have therapeutic advantages for the clinical treatment of inflammatory pain.
引用
收藏
页码:239 / 246
页数:8
相关论文
共 46 条
[1]   Advances in NSAID Development: Evolution of Diclofenac Products Using Pharmaceutical Technology [J].
Altman, Roy ;
Bosch, Bill ;
Brune, Kay ;
Patrignani, Paola ;
Young, Clarence .
DRUGS, 2015, 75 (08) :859-877
[2]   Participation of the anti-inflammatory and antioxidative activity of docosahexaenoic acid on indomethacin-induced gastric injury model [J].
Arlen Pineda-Pena, Elizabeth ;
Martinez-Perez, Yoalli ;
Galicia-Moreno, Marina ;
Navarrete, Araceli ;
Segovia, Jose ;
Muriel, Pablo ;
Favari, Liliana ;
Castaneda-Hernandez, Gilberto ;
Evangelina Chavez-Pina, Aracely .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 818 :585-592
[3]   Docosahexaenoic acid, an omega-3 polyunsaturated acid protects against indomethacin-induced gastric injury [J].
Arlen Pineda-Pena, Elizabeth ;
Miguel Jimenez-Andrade, Juan ;
Castaneda-Hernandez, Gilberto ;
Evangelina Chavez-Pina, Aracely .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2012, 697 (1-3) :139-143
[4]  
Ashworth NL, 2005, J RHEUMATOL, V32, P2212
[5]   17(R)-resolvin D1 specifically inhibits transient receptor potential ion channel vanilloid 3 leading to peripheral antinociception [J].
Bang, S. ;
Yoo, S. ;
Yang, T. J. ;
Cho, H. ;
Hwang, S. W. .
BRITISH JOURNAL OF PHARMACOLOGY, 2012, 165 (03) :683-692
[6]   Omega-3 Fatty Acid-Derived Mediators 17(R)-Hydroxy Docosahexaenoic Acid, Aspirin-Triggered Resolvin D1 and Resolvin D2 Prevent Experimental Colitis in Mice [J].
Bento, Allisson Freire ;
Claudino, Rafaela Franco ;
Dutra, Rafael Cypriano ;
Marcon, Rodrigo ;
Calixto, Joao B. .
JOURNAL OF IMMUNOLOGY, 2011, 187 (04) :1957-1969
[7]   Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials [J].
Bhala, N. ;
Emberson, J. ;
Merhi, A. ;
Abramson, S. ;
Arber, N. ;
Baron, J. A. ;
Bombardier, C. ;
Cannon, C. ;
Farkouh, M. E. ;
FitzGerald, G. A. ;
Goss, P. ;
Halls, H. ;
Hawk, E. ;
Hawkey, C. ;
Hennekens, C. ;
Hochberg, M. ;
Holland, L. E. ;
Kearney, P. M. ;
Laine, L. ;
Lanas, A. ;
Lance, P. ;
Laupacis, A. ;
Oates, J. ;
Patrono, C. ;
Schnitzer, T. J. ;
Solomon, S. ;
Tugwell, P. ;
Wilson, K. ;
Wittes, J. ;
Baigent, C. ;
Adelowo, O. ;
Aisen, P. ;
Al-Quorain, A. ;
Altman, R. ;
Bakris, G. ;
Baumgartner, H. ;
Bresee, C. ;
Carducci, M. ;
Chang, D-M. ;
Chou, C-T. ;
Clegg, D. ;
Cudkowicz, M. ;
Doody, L. ;
El Miedany, Y. ;
Falandry, C. ;
Farley, J. ;
Ford, L. ;
GarciLosa, M. ;
Gonzalez-Ortiz, M. ;
Haghighi, M. .
LANCET, 2013, 382 (9894) :769-779
[8]   Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? [J].
Calder, Philip C. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (03) :645-662
[9]  
Cleland LG, 2006, J RHEUMATOL, V33, P1973
[10]   ACUTE ANTIINFLAMMATORY ACTIVITY AND GASTROINTESTINAL TOLERABILITY OF DICLOFENAC AND NITROFENAC [J].
CONFORTI, A ;
DONINI, M ;
BROCCO, G ;
DELSOLDATO, P ;
BENONI, G ;
CUZZOLIN, L .
AGENTS AND ACTIONS, 1993, 40 (3-4) :176-180